Table 3.
Monitored adverse events and other events of interest by age and treatment group
| Age 70–97 years | Age 50–69 years | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Monitored adverse event | Rosuvastatin | Placebo | Hazard ratio† (95% CI) | Rosuvastatin | Placebo | Hazard ratio† (95% CI) | ||||
| N | Rate* | N | Rate* | N | Rate* | N | Rate* | |||
| Any serious adverse event | 622 | 10.93 | 584 | 10.45 | 1.05 (0.93–1.17) | 730 | 6.07 | 793 | 6.51 | 0.93 (0.84–1.03) |
| Muscle weakness, stiffness or pain | 494 | 8.92 | 467 | 8.50 | 1.04 (0.92–1.19) | 927 | 8.14 | 908 | 7.85 | 1.04 (0.94–1.13) |
| Myopathy | 4 | 0.06 | 3 | 0.05 | 1.31 (0.29–5.84) | 6 | 0.05 | 6 | 0.05 | 1.01 (0.33–3.14) |
| Rhabdomyolosis | 1 | 0 | 0 | 0 | ||||||
| Newly diagnosed cancer | 144 | 2.30 | 155 | 2.54 | 0.91 (0.73–1.14) | 154 | 1.21 | 159 | 1.23 | 0.98 (0.79–1.22) |
| Death from cancer | 18 | 0.27 | 31 | 0.48 | 0.58 (0.32–1.03) | 17 | 0.13 | 27 | 0.20 | 0.63 (0.35–1.16) |
| Gastrointestinal disorder | 665 | 12.41 | 621 | 11.71 | 1.06 (0.95–1.18) | 1088 | 9.72 | 1090 | 9.54 | 1.02 (0.94–1.11) |
| Renal disorder | 222 | 3.63 | 191 | 3.17 | 1.14 (0.94–1.39) | 313 | 2.51 | 289 | 2.28 | 1.10 (0.94–1.29) |
| Bleeding | 127 | 2.04 | 106 | 1.73 | 1.18 (0.91–1.53) | 131 | 1.03 | 169 | 1.32 | 0.78 (0.62–0.98) |
| Hepatic disorder | 61 | 0.96 | 59 | 0.95 | 1.01 (0.71–1.45) | 155 | 1.22 | 127 | 0.99 | 1.24 (0.98–1.57) |
| Newly diagnosed diabetes | 82 | 1.30 | 64 | 1.03 | 1.25 (0.90–1.74) | 188 | 1.48 | 152 | 1.18 | 1.26 (1.02–1.56) |
*
Rates are per 100 person-years
†
Hazard ratios compare hazards in the rosuvastatin group to placebo